In this study, we investigated the in vivo distribution of insoluble fluorescent microparticles administered to rats through the central vein. We previously reported that the IMs increased by mixed operation of some injections. The number of 10-25 μm insoluble microparticles was 41±1 /mL. Therefore, the daily 10-μm fluorescent microparticle dose was set at 2000/day for the nutritional solution dose of 50 mL/day required to maintain the rats. The fluorescent microparticles were administered by bolus injection into the central vein on Days 1, 2, and 3. A fluorescence microscope was used to assess frozen thin sections of each organ that were prepared on Day 4 and urine samples. A large number of fluorescent microparticles were found in the lung tissue, with 1-5 particles in each of the 20-μm thick and 25-mm 2 area sections. In 20-μm thick and 50-mm 2 area kidney tissue sections, the number of observed fluorescent microparticles ranged from 0.1 to 0.2. No fluorescent microparticles were detected in tissue samples from the veins, cerebrum, cerebellum, heart, or liver. The total number of fluorescent microparticles excreted in the urine was 283.4±113.0, which only accounted for approximately 4.7％ of the dose administered over the 3-day period. These findings suggest that 10 μm insoluble microparticles administered intravenously, accumulate mainly in the lungs and kidneys and are excreted at low levels in the urine.
Introduction
The Japanese Pharmacopoeia 16 th Edition (JP)
stipulates the permissible number of insoluble microparticles (IMs) per mL in injectables, as determined by light obscuration particle count test (Table 1) . 1) The pharmacopoeias of Japan, USA, and EU include the similar stipulations in this respect. We had previously reported that the IMs increased by mixed operation of some injections (50％ Glucose preparation, amino acid prepara-％ Glucose preparation, amino acid preparaGlucose preparation, amino acid preparation, 1 mol potassium chloride preparation, 10％ sodium chloride preparation, maintenance fluid, vitamin preparation, and H2 blocker preparation) .
2)
The number of 10 μm IMs exceeded the JP limits.
Therefore, we reported that in-line lters are useful for avoiding the risks associated with the infusion treatment methods due to such microparticles and are essential in cases wherein a possibility of administration of 2 or more injectable drugs exists. 2) In addition, after intravenous injection of mice with large doses of barium sulfate particles 1.5-10.0 μm in diameter, as surrogates for IMs, the particles were found to be distributed to all organs except the brain.
3)
The IMs of various types, forms, and a size are included in injection products. In this study, we examined the tissue distribution of them after injecting the different spherical fluorescent microparticles (FMs) from a rat central vein.
Materials and Methods

Experimental Animals
Seven-week-old male F344/DuCrlCrlj (Fischer 344) rats (Charles River Laboratories Japan, Inc.)
were reared in the husbandry section of the Research Building for 6 days and used in the study at the age of 8 weeks. During the rearing period, the rats were allowed free access to solid feed for laboratory animals (CRF-1, Oriental Yeast Co., Ltd.) and water from the beginning of the quarantine and acclimation period. However, the rats were not provided with either food or water dur- 
Study Method
The study schedule is shown in Fig. 1 24-h urine samples were collected at 10:00 hours before administration. In addition, because the study was completed at 16:00 hours on day 3, the 6-h (10:00-16:00 hours) urine samples were collected on that day. Each collected urine sample was centrifuged for 10 min at 3000 rpm, the supernatant was removed, the urine sediment was immediately observed under a fluorescence microscope, and the amount of FMs excreted in the urine was determined. The rats were transported from the husbandry section of the Research Building to the laboratory at Ohu University at 17:00 hours on day 3 and were euthanized by diethyl ether anesthesia at 9:00 hours on day 4. After venous blood was collected, the cerebrum, cerebellum, lung, heart, liver, and kidney were collected. These organs were then frozen and sectioned, and FM distribution in the tissues was immediately assessed by uorescence microscopy.
This study was performed in accordance with the "Guidelines for animal experiments" of Ohu 
Statistical Analysis
The statistical software used was StatView ® for Windows version 5.0 (SAS Institute, Inc., Cary, NC, USA). All measured values are expressed as mean±standard deviation. The weights of the rats in the control and FM groups at study initiation were compared using the Mann-Whitney Utest, and other comparisons between the groups were made using the unpaired two-group t-test.
The significance level was set at P < 0.05 in the two-sided tests.
Results
Body Weights
The body weights of the rats in the control group (176.6 ± 3.2 g, n = 8) were not signi cantly different from those in the FM group (176.9 ± 3.7 g, n = 8) (P = 0.9164).
Amount of FMs Excreted in Urine
The volumes of the urine samples collected from the control and FM groups are shown in Table 2 , and the number of FMs excreted is On days 1 to 3, the control and fluorescent microparticle groups received either a 1-mL bolus of saline or test suspension per rat through a central venous line once daily. On each day, 24-h urine samples were collected at 10:00 hours before administration. In addition, as the study was completed at 16:00 hours on day 3, the 6-h (10:00-16:00 hours) urine samples were collected on that day.
shown in Table 3 . The urine samples collected at 10:00 hours on days 1, 2, and 3 were termed as day-1, day-2, and day-3-1 samples, respectively, and those collected at 16:00 hours on day 3 were termed the day-3-2 samples. The day-1, day-2, and day-3-1 urine samples were collected at 24 h, whereas, the day-3-2 urine samples were collected at 6 h.
The urine volumes in the control group were as follows: day-1, 32.4±1.5 mL; day-2, 39.6±2. 
FM Distribution in the Tissues
FM distribution in the different rat organs is shown in Table 4 , and FM images in lungs and kidneys are shown in Fig. 2 The day-1, day-2, and day-3-1 samples were 24-h urine samples, whereas the day-3-2 samples were 6-h urine samples. Data are mean±standard deviation. Unpaired two-group t-test. n = 8. NS : not significant. Table 3 Number of fluorescent microparticles (FMs) excreted in the urine 10 mm×20 μm, ranged from 0.1 to 0.2. However, no FMs were found in the veins, cerebrum, cerebellum, heart, or liver.
Discussion
In this study, the FMs were administered to rats Adverse events associated with the use of IMs or foreign microparticles include phlebitis, pulmonary embolism, pulmonary granuloma, local tissue infarctions, and capillary and arterial occlusions; fatal cases have been reported. [10] [11] [12] [13] In addition, Lehr et al. 14) reported that the reduction in capillary perfusion due to the presence of microparticles was greater in muscle areas that suffered more severe damage and was dependent on the severity of muscle damage due to ischemia and/or reperfusion. This suggests that the administration of microparticle-containing drugs may cause damage to major organs because of factors, such as trauma, major surgery, and sepsis.
The different types of insoluble microparticles formed in clinical settings include rubber fragments from rubber stoppers, glass or plastic fragments from glass or plastic ampoules, silicone from plastic syringes, drug microparticles formed during changes on combination or dissolution of lyophilized agents, and matter formed from other infusion-related equipment or materials. [15] [16] [17] [18] [19] For preventing adverse events associated with the use of IMs, in-line lters can be used as they prevent IMs from entering the body. In-line lters are recommended in a number of guidelines, [20] [21] [22] [23] [24] [25] and we have always highly recommended their use.
In the present study, 0.1-and 1-μm particles were also administered using the same experimental system. However, because the 0.1-μm particles were uorescent red and the 1-μm particles were uorescent blue, their uorescence intensities were low and thus could not be detected by our fluorescence microscopy system. In a previous study, 2) a large number of microparticles 1-10 μm in diameter were detected. The distribution of IMs less than 10 μm in diameter may have been different from that observed in the present study.
In addition, admixed drugs contain not only IMs more than 1 μm in diameter but also those that are 1-1000 nm in diameter, and concerns have been raised that these smaller microparticles may also have adverse effects. 26, 27) On the contrary, microparticle-type carrier agents with particle diameters in the μm range that made use of the diameter-dependent differences in distribution have also been reported. 28) In the future, further consider-ation should be given to materials used in such studies, and research should be extended to cover IM 10 μm in diameter or less, which are not covered by the JP stipulations.
Conclusions
Even if suf cient care is used during admixture of drugs, IM may form or mix with the agents.
Because such microparticles are not visible to the naked eye, they can be administered unintentionally. Intravenously administered IM may accumulate in vital body tissues, which raises concerns about their potential negative effects on the human body. Therefore, we recommend the use of in-line filters for intravenous infusions. We believe that in particular, the use of in-line lters is essential in cases involving children, elderly patients, patients with microcirculatory damage to major organs, patients being treated in intensive care units who are at high risk for IM, and patients receiving multiple injectable drugs.
